What is asthma?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

What is Asthma?

Asthma is a chronic inflammatory disorder of the airways characterized by variable and recurring symptoms (wheezing, breathlessness, chest tightness, and cough), reversible airflow obstruction, bronchial hyperresponsiveness, and underlying inflammation involving multiple cell types including mast cells, eosinophils, T lymphocytes, and epithelial cells. 1

Core Pathophysiological Features

The disease manifests through three interconnected mechanisms that determine clinical severity and treatment response:

Airway Inflammation

Multiple cellular elements drive the inflammatory process 1:

  • Mast cells, eosinophils, neutrophils (particularly in sudden-onset fatal exacerbations, occupational asthma, and smokers)
  • T lymphocytes, macrophages, and epithelial cells
  • In susceptible individuals, this inflammation triggers recurrent episodes particularly at night or early morning

Airflow Limitation

The airways narrow through several inflammation-driven changes 1:

  • Bronchoconstriction: Bronchial smooth muscle contracts rapidly in response to allergens or irritants
  • Airway hyperresponsiveness: Exaggerated bronchoconstrictor response to various stimuli
  • Airway edema: Progressive inflammation leads to edema, mucus hypersecretion, and inspissated mucus plugs that further limit airflow

Airway Remodeling

Persistent structural changes can occur 1:

  • Sub-basement fibrosis
  • Mucus hypersecretion and epithelial cell injury
  • Smooth muscle hypertrophy
  • Angiogenesis
  • Important caveat: Reversibility of airflow limitation may be incomplete in some patients despite treatment

Clinical Presentation

Cardinal Symptoms 2

The hallmark symptoms are:

  • Wheeze (diffuse, polyphonic, bilateral, particularly expiratory)
  • Shortness of breath
  • Chest tightness
  • Cough (when predominant without wheeze, termed "cough variant asthma")

Characteristic Pattern

These symptoms are distinguished by being 2:

  • Variable and intermittent
  • Worse at night
  • Provoked by triggers including exercise, allergens, irritants, viral infections, cold air

Critical diagnostic point: Symptoms are associated with widespread but variable airflow obstruction that is often reversible either spontaneously or with treatment 1.

Disease Heterogeneity

Recent evidence reveals asthma is not a single disease but a syndrome with multiple phenotypes 1, 3:

Type 2 (T2) High Asthma

  • Characterized by eosinophilic inflammation
  • Defined by: absolute eosinophil count ≥300 cells/μL, FeNO ≥25 ppb, and/or sputum eosinophils ≥1-3% 4
  • Represents approximately 50% or more of severe asthma cases 4
  • Responds well to inhaled corticosteroids and biologic therapies

Type 2 Low Asthma

  • Comprises approximately 10-30% of the asthma population 4
  • Different inflammatory patterns and therapeutic responses
  • May involve neutrophilic inflammation

Allergic Asthma

  • Predominantly triggered by allergens
  • Associated with atopic conditions (eczema, allergic rhinitis) 2

Etiology and Risk Factors

The development involves interplay between 1:

  • Host factors: Particularly genetics
  • Environmental exposures: Occurring at crucial times in immune system development
  • Gene-environment interactions that are not fully understood 5

Common Triggers 2

  • Pollens, dust, feathered or furry animals
  • Exercise
  • Viral infections
  • Chemicals and environmental tobacco smoke
  • Aspirin/NSAIDs or beta-blockers

Epidemiology and Burden

  • Affects approximately 7.5% of adults and 10% of the European population 6, 7
  • Approximately 300 million people worldwide have asthma 8
  • Accounts for significant morbidity: emergency visits, hospitalizations, work/school absences
  • Severe asthma affects 5-10% of patients with asthma but constitutes nearly half of medical costs 4

Diagnostic Approach

The diagnosis is clinical - there is no confirmatory blood test, radiographic, or histopathological investigation 2. However, objective confirmation is essential:

Required Elements 7, 9

  1. Characteristic symptoms (as described above)
  2. Demonstration of reversible airway obstruction using spirometry
  3. Variable airflow limitation documented over time

Objective Testing 2

  • Spirometry: Decreased FEV1 and/or peak expiratory flow (PEF)
  • Bronchodilator reversibility testing
  • Peak flow variability: ≥20% variability in amplitude with minimum change of 60 L/min
  • Bronchial challenge testing (methacholine, mannitol) when spirometry is normal but symptoms persist

Important caveat: Lung function may be normal between episodes of bronchospasm; if repeatedly normal in the presence of symptoms, the diagnosis must be questioned 2.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.